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Background: A systemic immune-inflammation index (SII) based on neutrophil (N),
lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid
tumors. The aim of this study is to evaluate the prognostic role of SII in metastatic
castration-resistant prostate cancer (mCRPC) patients treated with abiraterone post
docetaxel.
Patients and Methods: We retrospectively reviewed consecutive mCRPC patients
treated with abiraterone after docetaxel in our Institutions. X-tile 3.6.1 software, cut-off
values of SII, neutrophil-to-lymphocyte ratio (NLR) defined as N/L and platelets-to-
lymphocyte ratio (PLR) as P/L. Overall survival (OS) and their 95% Confidence Intervals
(95% CI) was estimated by the Kaplan–Meier method and compared with the log-rank
test. The impact of SII, PLR, and NLR on overall survival (OS) was evaluated by
Cox regression analyses and on prostate-specific antigen (PSA) response rates were
evaluated by binary logistic regression.
Results: A total of 230 mCRPC patients treated abiraterone were included. SII ≥ 535,
NLR ≥ 3 and PLR ≥ 210 were considered as elevated levels (high risk groups. The
median OS was 17.3 months, 21.8 months in SII < 535 group and 14.7 months in
SII ≥ 535 (p < 0.0001). At univariate analysis Eastern Cooperative Oncology Group
(ECOG) performance status, previous enzalutamide, visceral metastases, SII, NLR,
and PLR predicted OS. In multivariate analysis, ECOG performance status, previous
enzalutamide, visceral metastases, SII, and NLR remained significant predictors of OS
[hazard ratio (HR) = 5.08, p < 0.0001; HR = 2.12, p = 0.009, HR = 1.77, 95%
p = 0.012; HR = 1.80, p = 0.002; and HR = 1.90, p = 0.001, respectively], whereas,
PLR showed a borderline ability only (HR = 1.41, p = 0.068).
Conclusion: SII and NLR might represent an early and easy prognostic marker in
mCRPC patients treated with abiraterone. Further studies are needed to better define
their impact and role in these patients.
Keywords: systemic immune-inflammation index, PSA, CRPC, prostate cancer, prognostic factor, abiraterone
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INTRODUCTION
Prostate cancer is the most common cancer and the second
cause of death for cancer in men (Siegel et al., 2016). Castration
resistance is an extremely heterogeneous condition ranging from
asymptomatic patients with only an initial increase of prostate-
specific antigen (PSA) to patients with high-volume of disease
and potentially heavily symptomatic (Attard et al., 2016). In
the last years, new agents prolonged survival and improved
quality of life of patients.with metastatic castration-resistant
prostate cancer (mCRPC), including abiraterone, enzalutamide,
cabazitaxel, sipuleucel T, and radium-223 (de Bono et al., 2010,
2011; Kantoff et al., 2010; Scher et al., 2012; Parker et al., 2013). In
order to better select treatment and sequencing of these drugs, the
identification of prognostic and predictive factors is increasingly
investigated.
The effect of inflammation in prognosis and progression
has been shown in patients with mCRPC, and peripheral
blood circulating cells (neutrophils, lymphocytes and platelets)
included in inflammation indices have been associated with
prognosis in these patients (De Marzo et al., 2007; Brennen et al.,
2013; Leibowitz-Amit et al., 2014; Lorente et al., 2015; Conteduca
et al., 2016). Neutrophil-to-lymphocyte ratio (NLR) and
platelets-to-lymphocyte ratio (PLR) are markers of inflammation
associated with prognosis in several cancers (Templeton et al.,
2014; Cannon et al., 2015; Rossi et al., 2015). Recently, NLR
has shown a prognostic role in patients with mCRPC also when
treated with abiraterone, enzalutamide, docetaxel, or cabazitaxel
(Leibowitz-Amit et al., 2014; Nuhn et al., 2014; Lorente et al.,
2015; Conteduca et al., 2016). Systemic immune-inflammation
index (SII), a novel inflammatory index based on neutrophil,
TABLE 1 | Patient characteristics.
Total (N = 230) No. (%)
Age
Median value (range), years 74(45− 90)
ECOG performance status
0 102(44.3)
1 115(50.0)
2 13(5.7)
Gleason score
<8 75(36.8)
≥8 129(63.2)
Unknown/missing 26
Sites of metastasis
Bone only 85(37.0)
Nodal only 22(9.6)
Bone+nodal 88(38.3)
Visceral 35(15.2)
Previous chemotherapy
1 line 170(73.9)
>1 line 60(26.1)
Previous enzalutamide
No 209(90.9)
Yes 21(9.1)
lymphocyte, and platelet counts, has recently emerged as a
powerful prognostic index in hepatocarcinoma, renal cell cancer,
and colorectal (Hu et al., 2014; Lolli et al., 2016; Passardi et al.,
2016), but to date no data have been reported in mCRPC.
In this retrospective analysis, we aimed to evaluate prognostic
implications of SII at baseline and changes during treatment
with abiraterone in patients with mCRPC post-docetaxel. In
addition, we considered also NLR and PLR value and their
respective changes at 4 weeks to try to better define the impact
of these inflammatory indexes on mCRPC patients treated with
abiraterone.
PATIENTS AND METHODS
We retrospectively evaluated 230 patients with mCRPC treated
with abiraterone in the post docetaxel setting between April 2011
and May 2015 in our seven Institutions. SII, the inflammatory
index based on platelets (P), neutrophils (N), and lymphocytes
(L) counts, was defined as P × N/L. In order to determine the
cutoff value of SII, NLR defined as N/L and PLR as P/L at the
baseline data, the X-tile 3.6.1 software (Yale University, New
Haven, CT, USA) was used.
Data were collected into electronic data files by the local
physicians and checked at the central data management. Patients
not treated with docetaxel before abiraterone (pre chemotherapy
setting) were not considered for the analysis.
Abiraterone was administered according to clinical practice
at the dose of 1000 mg once daily and was associated with
prednisone 5 mg BID. Patients were treated until disease
progression or unacceptable toxicity occurred. All patients
provided written informed consent. All recorded PSA test, full
blood examinations, including a complete blood count, and scan
results were retrospectively collected for these patients, evaluated
commonly every 4 weeks for serologic PSA response and as
clinically indicated for imaging assessment. PSA response was
FIGURE 1 | Kaplan–Meier plots illustrating overall survival in the
patient population.
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FIGURE 2 | Overall survival according to baseline systemic
immune-inflammation index (SII), neutrophil-to-lymphocyte ratio
(NLR), and platelets-to-lymphocyte ratio (PLR) indexes. Kaplan–Meier
plots illustrating overall survival according to baseline SII ≥ 535 vs. < 535
(p < 0.0001) (A), NLR ≥ 3 vs. < 3 (p < 0.0001) (B), and PLR ≥ 210
vs. < 210 (p = 0.002) (C).
defined according to the Prostate Cancer Working Group 2
criteria as a decline on serum PSA levels during abiraterone
treatment of 50% or more from PSA baseline value maintained
for ≥3 weeks (Scher et al., 2008). In addition, the PSA decline
of 30% or more after 4 weeks of treatment only has been
recently demonstrated as a useful predictive marker and was
considered for comparison with early inflammatory changes
(Rescigno et al., 2016). Monthly PSA measurements were
carried out during the first 3 months of abiraterone, and
thereafter every 1–3 months according to physicians’ discretion.
A clinical deterioration or a radiologic evidence of PD as
well as PSA increase associated with therapy interruption
secondary to unacceptable toxicity or death were sufficient to
establish abiraterone discontinuation. This study was carried
out in accordance with the approval of the local ethical
committee.
Primary Objective and Statistical
Analysis
The primary objective of this study was to evaluate the ability of
SII to predict the overall survival (OS) in patients with mCRPC
treated with abiraterone in post-docetaxel setting. As patients
were treated in clinical practice, radiological assessment was not
carried out at pre-determined intervals in most patients, so that
radiological progression-free survival (PFS) could not be assessed
for all patients.
Data were summarized by frequency for categorical variables
and by median and range for continuous variables. Association
between categorical variables was assessed using theχ2 or Fisher’s
exact test. Differences were considered statistically significant
when p < 0.05. OS was calculated from the start of abiraterone
until death or last follow-up. The Kaplan–Meier method was
used to estimate OS. The log-rank test and Cox proportional
hazard regression were used to test for differences between
groups. After univariate analysis, a multivariate analysis was
carried out by Cox regression model. Estimated hazard ratios
(HRs), their 95% confidence intervals (95% CI), and p values
were calculated from the Cox proportional hazard regression
models. The impact of inflammatory index conversion on
survival outcomes was evaluated by the landmark analysis
at 4 weeks. All statistical analyses were carried out with
SAS statistical software, version 9.4 (SAS Institute, Cary, NC,
USA).
RESULTS
A total of 230 mCRPC patients with a median age of 74 years
(range, 45–90 years) underwent abiraterone treatment post-
docetaxel were included in the study. Among all patients, 35
(15.2%) had visceral metastases, 21 (9.1%) received previous
enzalutamide. Patient characteristics at baseline are reported in
Table 1. The optimal cutoff point was calculated by X-tile 3.6.1
software to determine the best threshold of indices levels to
predict OS at 18 months, and for the SII was 535 × 109, for
NLR was 3 and PLR was 210. Then, SII ≥ 535, NLR ≥ 3,
and PLR ≥ 210 were considered as elevated levels (high-risk
groups). Visceral metastases were not associated with SII groups
(p = 0.479), whereas a trend versus an association with NLR
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TABLE 2 | Univariate analysis.
Overall Survival
Variables No. patients No. events Median Overall survival (OS) (months) (95% CI) Hazard ratio (HR) (95% CI) p-value
Overall 230 156 17.3 (14.7-18.9) – –
Age – – – 0.998 (0.977–1.020) 0.860
Gleason score
<8 75 52 15.2 (12.2–20.4) 1.00
≥8 129 85 17.4 (13.7–19.4) 0.91 (0.65–1.29) 0.612
ECOG performance status
0–1 217 145 17.7 (15.2–19.6) 1.00
≥2 13 11 8.7 (1.1–11.4) 3.52 (1.89–6.55) <0.0001
Sites of metastases
No visceral 195 130 18.1 (15.9–19.8) 1.00
Visceral 35 26 10.5 (7.0–15.5) 1.64 (1.07–2.50) 0.022
Previous chemotherapy treatment
1 line 170 109 16.8 (13.9–18.8) 1.00
>1 line 60 47 18.3 (13.7–21.8) 0.79 (0.55–1.12) 0.188
Previous enzalutamide
No 209 140 17.7 (15.2–19.6) 1.00
Yes 21 16 7.0 (5.2–15.5) 1.99 (1.18–3.35) 0.010
Neutrophil-to-lymphocyte ratio (NLR)
<3 126 85 20.4 (17.7–26.4) 1.00
≥3 104 71 14.7 (11.4–16.4) 2.13 (1.51–2.99) <0.0001
Platelets-to-lymphocyte ratio (PLR)
<210 151 100 19.0 (16.4–22.3) 1.00
≥210 79 56 14.4 (11.2–17.3) 1.68 (1.20–2.35) 0.002
SII
<535 98 64 21.8 (18.8–27.4) 1.00
≥535 132 92 14.7 (11.9–16.8) 2.08 (1.48–2.92) <0.0001
and PLR groups was reported (p = 0.057 and p = 0.055,
respectively).
PSA decline ≥50% during treatment from the baseline value
(PSA response) was assessable in 229 (99.6%) of 230 patients,
while PSA decline ≥30% at 4 weeks of treatment (early PSA
decline ≥30%) was evaluable in 211 (91.7%) cases. PSA response
was reported in 92 (40.2%) of 229 evaluable patients, while
early PSA decline ≥30% was reported in 93 (44.1%) of 211
evaluable patients. No association was observed among PSA
response and SII and NLR, with a trend for PLR (p = 0.126,
p = 0.709, and p = 0.057, respectively), whereas an association
with early PSA decline≥30% was observed for PLR (p= 0.0004),
a trend was seen for SII (p = 0.081), with no association with
NLR (p = 0.357). We also divided up the two baseline groups
(baseline high risk and low risk) of the three parameters (SII,
NLR, and PLR) on the basis of the values at 4 week (4-week
high risk and low risk), obtaining four subgroups: low–low,
low–high, high–low, and high–high. We then compared the
4-week conversion of SII, NLR, and PLR groups with PSA
response and early PSA decline ≥30%. PSA response was not
associated with 4-week conversions of NLR (p = 0.603), but a
trend was observed for SII, and PLR (p = 0.055 and p = 0.073,
respectively), whereas early PSA decline ≥30% was associated
with 4-week conversion of SII and PLR (p= 0.016 and p= 0.0003,
respectively) and a trend was observed with 4-week conversion of
NLR (p= 0.114).
After a median follow-up of 29 months (range, 1–55), 156
(67.8%) had died. The median OS was 17.3 months (95% CI
14.7–18.9; Figure 1). In relation to SII value, the median OS was
21.8 months (95 % CI 18.8–27.4) and 14.7 months (95% CI 11.9–
16.8) (p < 0.0001) in patients with baseline SII < 535 or ≥535,
respectively (Figure 2A). In relation to NLR value, the median
OS was 20.4 months (95% CI 17.7–26.4) and 14.7 months (95%
CI 11.4–16.4; p < 0.0001) in patients with baseline NLR < 3 or
≥3, respectively (Figure 2B). In relation to PLR value, the median
OS was 19.0 months (95% CI 16.4–22.3) and 14.4 months (95%
CI 11.2–17.3; p = 0.002) in patients with baseline PLR < 210
or ≥210, respectively (Figure 2C). A univariate analysis revealed
that Eastern Cooperative Oncology Group (ECOG) performance
status, previous enzalutamide, presence of visceral metastases
and all inflammatory indexes (SII, NLR, and PLR) were
significant predictors of OS (Table 2). In multivariate analysis,
among clinical variables, ECOG performance status, previous
enzalutamide therapy and presence of visceral metastases
remained significant predictors of OS (HR = 5.08, 95% CI 2.34–
10.99, p < 0.0001; HR = 2.12, 95% CI 1.20–3.73, p = 0.009, and
HR = 1.77, 95% CI 1.13–2.75, p = 0.012, respectively); whereas,
among inflammatory indexes, SII and NLR remained as predictor
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of OS (HR = 1.80, 95% CI 1.23–2.62, p = 0.002; and HR = 1.90,
95% CI 1.30–2.79, p= 0.001, respectively) whereas PLR showed a
borderline ability only (HR= 1.41, 95% CI 0.97–2.03, p= 0.068).
We studied the above-mentioned four conversion subgroups
of SII, NLR and PLR for OS. The high–high group showed a
significantly worse OS than low–low group with all inflammatory
indices, whereas results in the low–high and high–low groups
remained less significant (Table 3).
DISCUSSION
Our results confirmed the activity of abiraterone in post-
docetaxel setting in routinely clinical practice with a PSA
response rate of 44.5% and a median OS of 17.3 months
comparable to results of the pivotal phase III clinical trial (de
Bono et al., 2011). The prognostic significance of NLR, PLR, and
percentage of lymphocytes evaluate before systemic treatment
was shown in several tumors (De Giorgi et al., 2012; Templeton
et al., 2014; Cannon et al., 2015; Rossi et al., 2015), while SII
to date has been evaluated before antiangiogenic agents only in
CRC and RCC (Lolli et al., 2016; Passardi et al., 2016). Herein,
we reported for the first time SII to be an independent predictor
of OS for patients with mCRPC treated with abiraterone, a
recently approved hormonal therapy in mCRPC. Its ability to
predict OS was higher than conventional parameters such as
Gleason score (Table 2). We also confirmed previous data on the
OS prediction ability of NLR in these patients (Leibowitz-Amit
et al., 2014), whereas PLR showed a borderline significance in
the multivariate analysis (HR = 1.41, p = 0.068). Our results
suggest a possible prominent prognostic role for neutrophil
levels, included in SII and NLR, but not in PLR. In our study,
there was not a significant predictive role of these inflammatory
indexes for PSA response. In a previous study, other authors
analyzed the impact of NLR in mCRPC patients treated with
abiraterone showing ability to predict PSA response and OS.
However, the authors established the PSA response as the primary
objective instead of OS, which was not used since most patients
were alive at the time of that analysis (Leibowitz-Amit et al.,
2014). The continuous variable NLR was dichotomized using
optimal cutoffs of NLR = 5, which retained association with the
primary end point, the PSA response, by univariate analysis. In
our study, 156 (67.8%) of 230 patients had died at the time of
analysis, then we used OS as primary end point, and performed
ROC curve analysis to determine the best threshold of indices
levels to predict OS at 18 months; ROC curves identified the
cut-off values for NLR of 3. This difference in the definition
of the NLR threshold could have at least in part influenced
the different ability of NLR to predict PSA response in each
study. In addition, other limitations should be recognized as
the retrospective nature of the analysis and the relative under-
representation of some groups as ECOG performance status = 2
(15%) and patients pre-treated with enzalutamide (9%). Another
limiting factor is missing validation group of patients, thus the
study should be considered as hypothesis generating for next
larger and/or prospective studies.
We also evaluate the potential role of 4-week changes of
SII, NLR, and PLR on the prognosis (Table 3). The high–high
groups showed a significantly worse OS than low–low groups
with all inflammatory indices, whereas results in the low–high
and high–low groups remained more controversial, even if these
latest groups were poorly represented counting from 3.5 to 12.2%
in all three inflammatory indexes (Table 3). Another possible
limitation for the interpretation of these early changes may be
the use of prednisone 5 mg BID in combination with abiraterone,
which could influence these inflammatory indexes. In a large
study in 755 patients with mCRPC treated with chemotherapy
and prednisone 5 mg BID, the conversion of NLR counts from
high–low had a significant impact on the OS, whereas the change
from low to high did not modify the prognosis (Lorente et al.,
2015). There is lacking information in the literature on the
TABLE 3 | Changes in indices and clinical outcome.
Overall Survival
Variables n. patients n. events Median OS (months) (95% CI) HR (95% CI) p-value
NLR
Low–Low (<3–<3) 107 70 21.8 (17.6− 27.0) 1.00
Low–High(<3–≥3) 19 15 18.8 (12.2− 29.0) 1.49 (0.84–2.63) 0.169
High–Low(≥3–<3) 22 20 13.4 (7.8− 15.9) 3.22 (1.89–5.49) < 0.0001
High–High (≥3–≥3) 81 50 15.5 (11.8− 18.4) 2.04 (1.39–3.01) 0.0003
PLR
Low–Low (<210–<210) 142 92 19.3 (15.2− 24.6) 1.00
Low–High (<210–≥210) 8 7 18.6 (2.2− 30.1) 1.54 (0.71–3.33) 0.274
High–Low (≥210–<210) 28 21 13.7 (9.5− 18.8) 1.46 (0.91–2.36) 0.116
High–High (≥210–≥210) 51 35 14.4 (9.7− 17.4) 2.01 (1.34–3.01) 0.0008
SII
Low–Low (<535–<535) 79 50 25.9 (18.8− 29.6) 1.00
Low–High (<535–≥535) 19 14 19.4 (14.2− 27.0) 1.31 (0.72–2.38) 0.372
High–Low (≥535–<535) 24 15 16.4 (10.9− 18.1) 1.79 (0.99–3.22) 0.054
High–High (≥535–≥535) 107 76 13.9 (11.4− 17.3) 2.29 (1.57–3.33) < 0.0001
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association of inflammatory indexes and poor prognosis variants
of mCRPC, as presence of visceral metastases, neuroendocrine
differentiation, AR gene amplification or mutations (Burgio et al.,
2014; Conteduca et al., 2014, 2015; Azad et al., 2015; Salvi et al.,
2015). In our study the presence of visceral metastases, even
if poorly represented (n = 35, 15.2%), was initially associated
with NLR and PLR poor prognosis groups (p = 0.057 and
p = 0.055, respectively), showing possible correlations between
systemic inflammatory activation and more aggressive mCRPC
behavior.
In the last decade, circulating tumor cell (CTC) counts has
emerged as a biomarker for assessing prognosis and treatment
outcome in mCRPC (de Bono et al., 2008), Moreover, post-
treatment CTC changes has been associated with mCRPC
survival, and it has been shown that CTC count has superior
performance to other circulating biomarkers including PSA
(Lorente et al., 2016).
The prognostic role of the SII might be elucidated by the
function of peripheral N, L, and P and the their relationship
with CTC (De Giorgi et al., 2016; Mego et al., 2016). Our results
suggest the SII and NLR could be a more objective marker than
indexes such as the PLR. A better understanding of the role of
N, L, and P will help elucidate the association between cancer,
inflammation, and immunity.
The SII biomarker could represent a novel predictive marker
of clinical outcome to other treatments such as chemotherapy,
radium, radiotherapy, and should be tested in these clinical
situations.
A potential role for new immune check-point inhibitors in
combination with new hormonal therapies in mCRPC has been
recently suggested (Bishop et al., 2015; Graff et al., 2016), then
the identification of useful inflammatory-immune biomarkers
will be crucial for the development of these new drugs for
these patients (Saylor et al., 2012). The impact of immune-
inflammation indexes at baseline and during abiraterone (and
possibly enzalutamide) underlie a potential increase of immune-
inflammation biomarkers during these treatments. Potential use
of these biomarkers to predict the effect of immune-check-point
inhibitors alone or in combination with abiraterone in CRPC.
CONCLUSION
Inflammation deserves a pivotal role in prostate cancer
carcinogenesis and progression. Our results suggest that SII and
NLR can provide clinically meaningful information and might
represent an early and easy prognostic marker needing further
studies in mCRPC patients.
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